FDA Approves GSK’s Hibsago for Chronic Hepatitis B Treatment
GSK announced that the FDA approved Hibsago (bepirovirsen) for chronic hepatitis B treatment in the U.S.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA Approves GSK’s Hibsago for Chronic Hepatitis B
The FDA approved Hibsago (bepirovirsen) for chronic hepatitis B in adults receiving nucleos(t)ide analogue reverse transcriptase inhibitor therapy.